NCT01369745View on ClinicalTrials.gov

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2012

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Prednisolone

Prednisolone 2.7 mg daily

DRUG

dipyridamole

dipyridamole 360 mg daily

DRUG

Prednisone

Prednisone 5 mg daily

DRUG

Z102

Prednisolone 2.7 mg plus dipyridamole 360 mg daily

OTHER

placebo

Trial Locations (1)

43606

Zalicus Investigational Site, Toledo

Sponsors

Lead Sponsor

Zalicus
All Listed Sponsors
lead

Zalicus

INDUSTRY

NCT01369745 - A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter